[1] |
Elliott PM, Anastasakis A, Borger MA, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC)[J]. Eur Heart J, 2014, 35(39): 2733-2779. doi: 10.1093/eurheartj/ehu284
|
[2] |
Maron BJ, Maron MS. Hypertrophic cardiomyopathy[J]. Lancet, 2013, 381(9862): 242-255. doi: 10.1016/S0140-6736(12)60397-3
|
[3] |
Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the american college of cardiology/american heart association joint committee on clinical practice guidelines[J]. Circulation, 2020, 142(25): e558-e631.
|
[4] |
Ho CY, Lakdawala NK, Cirino AL, et al. Diltiazem treatment for pre-clinical hypertrophic cardiomyopathy sarcomere mutation carriers: a pilot randomized trial to modify disease expression[J]. JACC Heart Fail, 2015, 3(2): 180-188. doi: 10.1016/j.jchf.2014.08.003
|
[5] |
Green EM, Wakimoto H, Anderson RL, et al. A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice[J]. Science, 2016, 351(6273): 617-621. doi: 10.1126/science.aad3456
|
[6] |
Heitner SB, Jacoby D, Lester SJ, et al. Mavacamten treatment for obstructive hypertrophic cardiomyopathy: a clinical trial[J]. Ann Intern Med, 2019, 170(11): 741-748. doi: 10.7326/M18-3016
|
[7] |
Ho CY, Mealiffe ME, Bach RG, et al. Evaluation of Mavacamten in symptomatic patients with nonobstructive hypertrophic cardiomyopathy[J]. J Am Coll Cardiol, 2020, 75(21): 2649-2660. doi: 10.1016/j.jacc.2020.03.064
|
[8] |
Olivotto I, Oreziak A, Barriales-Villa R, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet, 2020, 396(10253): 759-769. doi: 10.1016/S0140-6736(20)31792-X
|
[9] |
Maron MS, Masri A, Choudhury L, et al. Phase 2 study of aficamten in patients with obstructive hypertrophic cardiomyopathy[J]. J Am Coll Cardiol, 2023, 81(1): 34-45. doi: 10.1016/j.jacc.2022.10.020
|
[10] |
Maurer MS, Hanna M, Grogan M, et al. Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey)[J]. J Am Coll Cardiol, 2016, 68(2): 161-172. doi: 10.1016/j.jacc.2016.03.596
|
[11] |
Elliott P, Drachman BM, Gottlieb SS, et al. Long-term survival with tafamidis in patients with transthyretin amyloid cardiomyopathy[J]. Circ Heart Fail, 2022, 15(1): e008193. doi: 10.1161/CIRCHEARTFAILURE.120.008193
|
[12] |
Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy[J]. N Engl J Med, 2018, 379(11): 1007-1016. doi: 10.1056/NEJMoa1805689
|
[13] |
McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC[J]. Eur J Heart Farl, 2021, 42(36): 3599-3726. doi: 10.1093/eurheartj/ehab368
|
[14] |
Solomon SD, Adams D, Kristen A, et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis[J]. Circulation, 2019, 139(4): 431-443. doi: 10.1161/CIRCULATIONAHA.118.035831
|
[15] |
Dasgupta NR, Rissing SM, Smith J, et al. Inotersen therapy of transthyretin amyloid cardiomyopathy[J]. Amyloid, 2020, 27(1): 52-58. doi: 10.1080/13506129.2019.1685487
|
[16] |
Gillmore JD, Gane E, Taubel J, et al. CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis[J]. N Engl J Med, 2021, 385(6): 493-502. doi: 10.1056/NEJMoa2107454
|
[17] |
Germain DP. Fabry disease[J]. Orphanet J Rare Dis, 2010, 5: 30. doi: 10.1186/1750-1172-5-30
|
[18] |
Vardarli I, Rischpler C, Herrmann K, et al. Diagnosis and screening of patients with fabry disease[J]. Ther Clin Risk Manag, 2020, 16: 551-558. doi: 10.2147/TCRM.S247814
|
[19] |
Lee CL, Lin SP, Niu DM, et al. Fabry disease and the effectiveness of Enzyme Replacement Therapy (ERT) in Left Ventricular Hypertrophy (LVH) improvement: a review and meta-analysis[J]. Int J Med Sci, 2022, 19(1): 126-131. doi: 10.7150/ijms.66448
|
[20] |
Beck M, Ramaswami U, Hernberg-Ståhl E, et al. Twenty years of the Fabry Outcome Survey (FOS): insights, achievements, and lessons learned from a global patient registry[J]. Orphanet J Rare Dis, 2022, 17(1): 238. doi: 10.1186/s13023-022-02392-9
|
[21] |
Beck M, Hughes D, Kampmann C, et al. Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: a Fabry outcome survey analysis[J]. Mol Genet Metab Rep, 2015, 3: 21-27. doi: 10.1016/j.ymgmr.2015.02.002
|
[22] |
Germain DP, Weidemann F, Abiose A, et al. Analysis of left ventricular mass in untreated men and in men treated with agalsidase-β: data from the Fabry Registry[J]. Genet Med, 2013, 15(12): 958-965. doi: 10.1038/gim.2013.53
|
[23] |
Weidemann F, Niemann M, Breunig F, et al. Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment[J]. Circulation, 2009, 119(4): 524-529. doi: 10.1161/CIRCULATIONAHA.108.794529
|
[24] |
Germain DP, Hughes DA, Nicholls K, et al. Treatment of Fabry's disease with the pharmacologic chaperone migalastat[J]. N Engl J Med, 2016, 375(6): 545-555. doi: 10.1056/NEJMoa1510198
|
[25] |
Hughes DA, Nicholls K, Shankar SP, et al. Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in fabry disease: 18-month results from the randomised phase Ⅲ ATTRACT study[J]. J Med Genet, 2017, 54(4): 288-296. doi: 10.1136/jmedgenet-2016-104178
|
[26] |
Khan A, Barber DL, Huang J, et al. Lentivirus-mediated gene therapy for Fabry disease[J]. Nature Communi-cations, 2021, 12(1): 1178. doi: 10.1038/s41467-021-21371-5
|